Effects of the Elements Clinical Trial
Official title:
Effect of Panaceo Micro Activation (PMA)-Zeolite-Clinoptilolite on the Mineral Metabolism and Selected Blood Parameters (MMBP Study)
Verified date | October 2020 |
Source | General Hospital Pula |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The Panaceo Micro Activation (PMA) -zeolite s a certified medical device throughout the European Union and absorbs defined harmful substances (mainly heavy metals and ammonium ions) in the gastrointestinal tract, while at the same time the alkaline ions contained in the crystal lattice are released (Mg2+, Ca2+, K+, Na+). Through a recent study the main-effect of zeolite was defined (support/ strengthen the intestinal wall barrier) and as a side-effect the measurement of the mineral metabolism was included, without documenting any significant changes. Its potential in releasing minerals needs to be investigated further to broaden the knowledge from previous study-outcomes as described. Broadening this knowledge through measuring defined blood-parameters was the aim of this human trial.
Status | Completed |
Enrollment | 15 |
Est. completion date | June 15, 2016 |
Est. primary completion date | May 13, 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - healthy volunteers - at least 18 years old - provided informed consent Exclusion Criteria: - chronic disease including: - cancer, - renal disease, - neuro-degenerative, - metabolic disorders, - diabetic) - recent vaccinations, - pregnancy or breastfeeding, - food supplements (if taken regularly this should be continued also during the study and documented) |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
General Hospital Pula |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes of Liver parameters | Biochemical evaluation of LIVER PARAMETERS (aspartate-aminotransferase, alanine-aminotransferase, gamma-glutamyltransferase)
Referent values/range used for analyses: aspartate aminotransferase (AST): 8-38 U/L (Unit/litre) alanine aminotransferase (ALT): 10 - 48 U/L (Unit/litre) (lower values are not clinically relevant) Gamma-glutamyl transferase (GGT): Men: 11 - 55 U/L (Unit/litre) Woman: 9 - 35 U/L (Unit/litre) This parameters will be combined to report the LIVER function The statistical analysis will be performed between this three groups of data "Changes of standard blood parameters, main standard mineral level in the blood and main metal and contaminant in the blood " , time point at "Day 0" and "Day 28" in control group and healthy volunteer group and between the groups |
"Day 0" and "Day 28" | |
Primary | Changes of renal parameters | Biochemical evaluation of RENAL PARAMETERS (creatinine, evaluation of the glomerular filtration speed will be done by use of a specific formula)
Referent values/range used for analyses: CREAT: Woman: 63 - 107 µmol/L, Men: 79 - 125 µmol/L glomerular filtration (GF) - evaluation: G1>=90/ G2 60-80/G3a 45-59/G3b 30-40/G4 15-29/G5 <15. M: 11-32; F:8-30 µmol/l This parameters will be combined to report the RENAL function The statistical analysis will be performed between this three groups of data "Changes of standard blood parameters, main standard mineral level in the blood and main metal and contaminant in the blood " , time point at "Day 0" and "Day 28" in control group and healthy volunteer group and between the groups |
"Day 0" and "Day 28" | |
Primary | Changes of main standard mineral level in the blood | Evaluation of standard mineral panel
Analyses: Na and K assessment relie on indirect potentiometer analysis Zn concentrations in serum assessed by use of spectrophotometric method Biochemical evaluation of Fe, Ca and Mg were done by standard spectrophotometric methods. Evaluation of the glomerular filtration speed will be done by use of a specific formula. Referent values/ range used: Na: 137 - 146 mmol/L; K: 3,9 - 5,1 mmol/L; Zn: Men: 11,1-19,5 µmol/l, Woman:10,7-17,5 µmol/l; Fe: Men:11-32; Woman:8-30 umol/l Mg: 0,65 - 1,05 mmol/L Ca: 2,14 - 2,53 mmol/L The parameters will be combined for evaluation of the mineral metabolism The statistical analysis will be performed between this three groups of data "Changes of standard blood parameters, main standard mineral level in the blood and main metal and contaminant in the blood " , time point at "Day 0" and "Day 28" in control group and healthy volunteer group and between the groups |
"Day 0" and "Day 28" | |
Primary | Changes of main metal level in the blood | Evaluation of main mineral panel
for Pb, Hg, Cr, Cd, As, Al and Ni were inductively Coupled Plasma Mass Spectrometry-ICP-MS analysis of serum and plasma samples Referent values/range used: Lead (Pb) = 50 µg/L Mercury (Hg) <10 µg/L Cadmium (Cd) < 1 µg/L Chromium (Cr) < 1 µg/L Arsenic (As) < 12µg/L Aluminium (Al) < 8 µg/L Nickel (Ni) < 2 µg/L The parameters will be combined for evaluation of the metal level The statistical analysis will be performed between this three groups of data "Changes of standard blood parameters, main standard mineral level in the blood and main metal and contaminant in the blood " , time point at "Day 0" and "Day 28" in control group and healthy volunteer group and between the groups |
"Day 0" and "Day 28" | |
Primary | Changes of Meathemoglobin in the blood | Methemoglobinemia is a condition of elevated methemoglobin in the blood causing headache, dizziness, shortness of breath, nausea....
Analyses for MHgb - methaemoglobin: The method relies on CO-oximetry by use of GEM OPLTM analyser Referent values/range used for analyses: methaemoglobin (MHgb) : 0-1,5% The statistical analysis will be performed between this three groups of data "Changes of standard blood parameters, main standard mineral level in the blood and main metal and contaminant in the blood " , time point at "Day 0" and "Day 28" in control group and healthy volunteer group and between the groups |
"Day 0" and "Day 28" |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05100615 -
Healing Assessment of Osseous Defects After Surgical Removal of Periapical Lesions
|
N/A | |
Completed |
NCT05445362 -
Efficacy of Diode Laser in Maturogenesis of Immature Teeth With Necrotic Pulps
|
N/A | |
Completed |
NCT04761211 -
Effect and Safety of Smart Bra (PUMCH)
|
N/A | |
Recruiting |
NCT04338633 -
Post-operative Pain Reduction
|
N/A | |
Recruiting |
NCT04327453 -
Effect of Removal of Double Antibiotic Paste on Post Operative Pain
|
N/A | |
Recruiting |
NCT04324086 -
Effect of Removal of Intracanal Medication on Post Operative Pain
|
N/A |